{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:21Z","timestamp":1792783401666,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sant\u00e9 S.A.S."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00726-w","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:31:46Z","timestamp":1742733106000},"page":"813-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0997-8817","authenticated-orcid":false,"given":"Patrick","family":"Vermersch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Paret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96\u2013120.","journal-title":"Mult Scler"},{"key":"726_CR2","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/ene.14790","volume":"28","author":"X Moisset","year":"2021","unstructured":"Moisset X, Fouchard AA, Pereira B, et al. Untreated patients with multiple sclerosis: a study of french expert centers. Eur J Neurol. 2021;28:2026\u201336.","journal-title":"Eur J Neurol"},{"key":"726_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.647811","volume":"12","author":"J Hillert","year":"2021","unstructured":"Hillert J, Magyari M, Soelberg S\u00f8rensen P, et al. Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network. Front Neurol. 2021;12: 647811.","journal-title":"Front Neurol"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12883-020-01882-2","volume":"20","author":"DM Kern","year":"2020","unstructured":"Kern DM, Cepeda MS. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurol. 2020;20:296.","journal-title":"BMC Neurol"},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"175628641989207","DOI":"10.1177\/1756286419892077","volume":"12","author":"M M\u00e4urer","year":"2019","unstructured":"M\u00e4urer M, Tiel-Wilck K, Oehm E, et al. Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419892077.","journal-title":"Ther Adv Neurol Disord"},{"key":"726_CR6","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.5409","volume":"18","author":"V Risson","year":"2016","unstructured":"Risson V, Saini D, Bonzani I, Huisman A, Olson M. Patterns of treatment switching in multiple sclerosis therapies in US patients active on social media: application of social media content analysis to health outcomes research. J Med Internet Res. 2016;18: e62.","journal-title":"J Med Internet Res"},{"key":"726_CR7","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00415-012-6487-5","volume":"259","author":"O Outteryck","year":"2012","unstructured":"Outteryck O, Ongagna JC, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol. 2012;259:2293\u20138.","journal-title":"J Neurol"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40120-022-00430-z","volume":"12","author":"J De S\u00e8ze","year":"2023","unstructured":"De S\u00e8ze J, Suchet L, Mekies C, et al. The place of immune reconstitution therapy in the management of relapsing multiple sclerosis in France: an expert consensus. Neurol Ther. 2023;12:351\u201369.","journal-title":"Neurol Ther"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-2288-8-50","volume":"8","author":"LM Bachmann","year":"2008","unstructured":"Bachmann LM, M\u00fchleisen A, Bock A, ter Riet G, Held U, Kessels AG. Vignette studies of medical choice and judgement to study caregivers\u2019 medical decision behaviour: systematic review. BMC Med Res Methodol. 2008;8:50.","journal-title":"BMC Med Res Methodol"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/j.1475-6773.2004.00327.x","volume":"39","author":"JW Peabody","year":"2004","unstructured":"Peabody JW, Tozija F, Mu\u00f1oz JA, Nordyke RJ, Luck J. Using vignettes to compare the quality of clinical care variation in economically divergent countries. Health Serv Res. 2004;39:1951\u201370.","journal-title":"Health Serv Res"},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/healthcare11010007","volume":"11","author":"KSE Payton","year":"2022","unstructured":"Payton KSE, Gould JB. Vignette research methodology: an essential tool for quality improvement collaboratives. Healthcare (Basel). 2022;11:7.","journal-title":"Healthcare (Basel)"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.7326\/0003-4819-141-10-200411160-00008","volume":"141","author":"JW Peabody","year":"2004","unstructured":"Peabody JW, Luck J, Glassman P, et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med. 2004;141:771\u201380.","journal-title":"Ann Intern Med"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/PPA.S254427","volume":"14","author":"P Tur\u010d\u00e1ni","year":"2020","unstructured":"Tur\u010d\u00e1ni P, Ma\u0161kov\u00e1 J, H\u00faska J. Real-world treatment patterns of disease modifying therapy (DMT) for patients with relapse-remitting multiple sclerosis and patient satisfaction with therapy: results of the non-interventional SKARLET Study in Slovakia. Patient Prefer Adherence. 2020;14:1129\u201335.","journal-title":"Patient Prefer Adherence"},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12883-022-02738-7","volume":"22","author":"RJ Fox","year":"2022","unstructured":"Fox RJ, Mehta R, Pham T, Park J, Wilson K, Bonafede M. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis. BMC Neurol. 2022;22:211.","journal-title":"BMC Neurol"},{"key":"726_CR15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458513477925","volume":"19","author":"T Olsson","year":"2013","unstructured":"Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler. 2013;19:1533\u20138.","journal-title":"Mult Scler"},{"key":"726_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40120-020-00201-8","volume":"9","author":"R Alroughani","year":"2020","unstructured":"Alroughani R, Inshasi J, Al-Asmi A, et al. Disease-modifying drugs and family planning in people with multiple sclerosis: a consensus narrative review from the Gulf region. Neurol Ther. 2020;9:265\u201380.","journal-title":"Neurol Ther"},{"key":"726_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","volume":"22","author":"KM Krysko","year":"2023","unstructured":"Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350\u201366.","journal-title":"Lancet Neurol"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","volume":"19","author":"R Dobson","year":"2019","unstructured":"Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: \u201cAssociation of British Neurologists\u201d guidelines. Pract Neurol. 2019;19:106\u201314.","journal-title":"Pract Neurol"},{"key":"726_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105751","volume":"88","author":"S Papukchieva","year":"2024","unstructured":"Papukchieva S, Kim HD, Stratil AS, et al. Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis. Mult Scler Relat Disord. 2024;88: 105751.","journal-title":"Mult Scler Relat Disord"},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269:5382\u201394.","journal-title":"J Neurol"},{"key":"726_CR21","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","volume":"271","author":"BA Singer","year":"2024","unstructured":"Singer BA, Feng J, Chiong-Rivero H. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. J Neurol. 2024;271:3116\u201330.","journal-title":"J Neurol"},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol. 2024;271:105\u201315.","journal-title":"J Neurol"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"175628642412378","DOI":"10.1177\/17562864241237857","volume":"17","author":"S Papukchieva","year":"2024","unstructured":"Papukchieva S, Stratil AS, Kahn M, et al. Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis\u2014real-world evidence from Germany. Ther Adv Neurol Disord. 2024;17:17562864241237856.","journal-title":"Ther Adv Neurol Disord"},{"key":"726_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102925","volume":"51","author":"M Al Jumah","year":"2021","unstructured":"Al Jumah M, Abulaban A, Aggad H, et al. Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia. Mult Scler Relat Disord. 2021;51: 102925.","journal-title":"Mult Scler Relat Disord"},{"key":"726_CR25","first-page":"182","volume":"40","author":"DC Morrell","year":"1990","unstructured":"Morrell DC, Roland MO. Analysis of referral behaviour: responses to simulated case histories may not reflect real clinical behaviour. Br J Gen Pract. 1990;40:182\u20135.","journal-title":"Br J Gen Pract"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ctn7010002","volume":"7","author":"C Friedli","year":"2023","unstructured":"Friedli C, Salmen A, Hoepner R, et al. Specific aspects of immunotherapy for multiple sclerosis in switzerland\u2014a structured commentary, update 2022. Clin Transl Neurosci. 2023;7:2.","journal-title":"Clin Transl Neurosci"},{"key":"726_CR27","first-page":"20","volume":"24","author":"C Friedli","year":"2024","unstructured":"Friedli C, Salmen A, Hoepner R, et al. Particularit\u00e9s de l\u2019immunoth\u00e9rapie de la scl\u00e9rose en plaques en Suisse: mise \u00e0 jour. Forum M\u00e9dical Suisse. 2024;24:20\u20137.","journal-title":"Forum M\u00e9dical Suisse"},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s40001-023-01185-5","volume":"28","author":"V Gitman","year":"2023","unstructured":"Gitman V, Moss K, Hodgson D. A systematic review and meta-analysis of the effects of non-pharmacological interventions on quality of life in adults with multiple sclerosis. Eur J Med Res. 2023;28:294.","journal-title":"Eur J Med Res"},{"key":"726_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/1570159X15666171109132650","volume":"16","author":"E Miller","year":"2018","unstructured":"Miller E, Morel A, Redlicka J, Miller I, Saluk J. Pharmacological and non-pharmacological therapies of cognitive impairment in multiple sclerosis. Curr Neuropharmacol. 2018;16:475\u201383.","journal-title":"Curr Neuropharmacol"},{"key":"726_CR30","first-page":"55","volume":"13","author":"E Faraclas","year":"2023","unstructured":"Faraclas E. Interventions to improve quality of life in multiple sclerosis: new opportunities and key talking points. Degener Neurol Neuromuscul Dis. 2023;13:55\u201368.","journal-title":"Degener Neurol Neuromuscul Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00726-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T09:58:25Z","timestamp":1747648705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00726-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00726-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrick Vermersch received fees for consultancy, advisory board and scientific meetings from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA, Roche, Imcyse, AB Science, Janssen, Ad Scientiam and BMS, and research support. from Novartis, Sanofi-Genzyme, Roche and Merck. Xavier Moisset received financial support from Allergan-Abbvie, Aptis Pharma, Biogen, BMS-Celg\u00e8ne, Gr\u00fcnenthal, Lilly, Lundbeck, Teva, Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA, Novartis, Orion, Pfizer, Roche, and Sanofi-Genzyme and non-financial support from SOS Oxyg\u00e8ne unrelated to the current work. J\u00e9r\u00f4me de S\u00e8ze received fees for consultancy, advisory board and scientific meetings from Novartis, Biogen, Sanofi, Roche, Janssen, Merck Sant\u00e9 S.A.S, Lyon, France, an affiliate of Merck KGaA, Alexion, CSL Behring, Horizon Therapeutics, LFB, Sandoz, and Pfizer. Baptiste Roux and Anais Lecomte are employees of Soci\u00e9t\u00e9 Fast4, Montpellier, France. Laura Luciani is an employee of Merck Sant\u00e9 S.A.S, Lyon, France, an affiliate of Merck KGaA. Martine Paret is an employee of Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study used fictional cases and does not fall within the scope of Articles L.1121\u20131 and following of the French Public Health Code. Given the nature of the study and the absence of real patient data, the protocol did not require submission to an Institutional Review Board (IRB) or Ethics Committees for approval. Therefore, IRB approval was not required. All participants were informed of the study objectives during recruitment phase. This communication was integral to ensuring that participants understood the purpose and significance of the study. Also, participants were made aware at this time that the results of the study would be published. Participants agreed to participate by providing verbal consent during the recruitment phase and were informed that they could withdraw from the study at any time without any consequences, ensuring their autonomy and comfort throughout the process. The independence of participants was verified as they completed the questionnaire autonomously on their personal devices, including phones, tablets, or computers, thus ensuring that their responses were not influenced by external factors. The protection of individuals\u2019 data was maintained rigorously in accordance with the guidelines specified in the Information Security and Privacy Policy (ISSP). Detailed information regarding these protocols can be provided upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}